2023-08-09 10:51:01 ET
- Results from a preclinical study of Hoth Therapeutics' ( NASDAQ: HOTH ) HT-ALZ for Alzheimer's disease found that the candidate led to improvement in areas of cognitive function.
- More specifically, benefits were seen with spatial learning and memory, sensorimotor gating, and contextual associative memory.
- The asset also showed a reduction in anxiety-type behavior in mice.
- Due to the positive results, Hoth will begin formulation development of HT-ALZ.
- Seeking Alpha's Quant Rating has viewed Hoth ( HOTH ) as a strong sell since Feb. 24 .
For further details see:
Hoth Therapeutics touts preclinical results for Alzheimer's asset